StemCell Institute (JP:7096)
:7096
Want to see JP:7096 full AI Analyst Report?
7096 Stock Chart & Stats
¥793.00
¥110.00(8.02%)
At close: 4:00 PM EST
¥793.00
¥110.00(8.02%)
Day’s Range― - ―
52-Week Range¥744.00 - ¥1,380.00
Previous CloseN/A
Volume70.10K
Average Volume (3M)28.64K
Market Cap
¥7.88B
Enterprise Value¥5.32B
Total Cash (Recent Filing)¥2.71B
Total Debt (Recent Filing)¥497.26M
Price to Earnings (P/E)33.5
Beta0.43
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.12
Shares Outstanding10,246,600
10 Day Avg. Volume23,150
30 Day Avg. Volume28,640
Financial Highlights & Ratios
PEG Ratio1.47
Price to Book (P/B)5.29
Price to Sales (P/S)5.19
P/FCF Ratio-1.37K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)16.9
Revenue Forecast (FY)¥3.20B
Bulls Say, Bears Say
Bulls Say
High Gross And Net MarginsSustained high gross margin (63.16%) and improving net margin (14.40%) indicate durable pricing power and efficient cost structure. These margins support reinvestment in R&D and commercialization, providing a structural buffer against revenue volatility and enabling long-term profitability.
Conservative Leverage And Capital StructureA low debt-to-equity ratio (0.20) and solid equity ratio (35.02%) provide financial flexibility for multi-quarter investments or setbacks. The conservative leverage lowers bankruptcy risk, permits opportunistic M&A or R&D spending, and supports resilience across business cycles.
Operating Cash ConversionOperating cash flow exceeding net income (OCF/NI = 1.21) shows the core business converts earnings into cash reliably. This structural cash generation supports sustainable operations and funding of strategic projects, even if capital spending timing varies.
Bears Say
Negative Free Cash Flow TrendA shift to negative free cash flow and a year-over-year decline signal structural pressure from capex or working capital. Persistently negative FCF can force external financing, constrain strategic investments, and reduce margin of safety over a multi-quarter horizon.
Declining EPS GrowthA steep EPS decline (~-51%) indicates weakening per-share earnings momentum and potential volatility in core profitability. If this reflects operational issues or one-offs that persist, it undermines sustainable earnings power and could limit long-term reinvestment capacity.
Modest Revenue Growth RateSingle-digit revenue growth (~5.5%) is modest for a biotech firm and may be insufficient to scale fixed costs or offset R&D intensity. Over several quarters, slower top-line expansion can pressure future margin expansion and constrain competitive investment.
StemCell Institute News
7096 FAQ
What was StemCell Institute’s price range in the past 12 months?
StemCell Institute lowest stock price was ¥744.00 and its highest was ¥1380.00 in the past 12 months.
What is StemCell Institute’s market cap?
StemCell Institute’s market cap is ¥7.88B.
When is StemCell Institute’s upcoming earnings report date?
StemCell Institute’s upcoming earnings report date is May 13, 2026 which is in 23 days.
How were StemCell Institute’s earnings last quarter?
StemCell Institute released its earnings results on Feb 12, 2026. The company reported ¥6.12 earnings per share for the quarter, beating the consensus estimate of N/A by ¥6.12.
Is StemCell Institute overvalued?
According to Wall Street analysts StemCell Institute’s price is currently Overvalued.
Does StemCell Institute pay dividends?
StemCell Institute pays a Notavailable dividend of ¥25 which represents an annual dividend yield of N/A. See more information on StemCell Institute dividends here
What is StemCell Institute’s EPS estimate?
StemCell Institute’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does StemCell Institute have?
StemCell Institute has 10,246,600 shares outstanding.
What happened to StemCell Institute’s price movement after its last earnings report?
StemCell Institute reported an EPS of ¥6.12 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.296%.
Which hedge fund is a major shareholder of StemCell Institute?
Currently, no hedge funds are holding shares in JP:7096
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
StemCell Institute
StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of medical treatments using stem cells, as well as engages in banking of blood vessel cells businesses. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan. StemCell Institute Inc. is a subsidiary of Trim Medical Holdings Inc.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―